Publications
Review Articles
Original Research articles
Cancer Research, May 2017
Moran B, Rahman A, Palonen K, Lanigan FT, Gallagher WM.
Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy
Clinical Chemistry, April 2017
Duffy MJ, McDermott EW, Crown J.
Vitamin D analogues: Potential use in cancer treatment.
Critical Reviews in Oncology/Hematology, April 2017
Duffy MJ, Murray A, Synnott NC, O’Donovan N, Crown J
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Nature Reviews Cancer, April 2017
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
European Journal of Cancer, April 2017
Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F
MicroRNA Profiling of Exosomes
Methods in Molecular Biology, January 2017
Daly M, O’Driscoll L
Link to article
Cancer Research, May 2017
Moran B, Rahman A, Palonen K, Lanigan FT, Gallagher WM.
Circulating microRNAs in Cancer
Methods in Molecular Biology, November 2016
O’Brien KP, Ramphul E, Howard L, Gallagher WM, Malone C, Kerin MJ, Dwyer RM
Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology
Methods Molecular Biology, October 2016
Mulrane L, Gallagher WM, O’Connor DP.
The ADAMs family of proteases as targets for the treatment of cancer.
Cancer Biology Therapy, August 2017
Mullooly M, McGowan PM, CrownJ, Duffy MJ
Validated biomarkers: The key to precision treatment in patients with breast cancer
The Breast, August 2016
Duffy MJ, O’Donovan N, McDermott E, Crown J.
Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer
International Journal of Cancer, May 2016
Joyce DP,=Kerin MJ, Dwyer RM
Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
Expert Review of Molecular Diagnostics, May 2016
Walsh L, Gallagher WM, O’Connor DP, Ní Chonghaile T
Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine.
ASC Nano, March 2016
Fais S, O’Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro da Silva A, Del Portillo H, El Andaloussi S, Ficko Trček T, Furlan R, Hendrix A, Gursel I, Kralj-Iglic V, Kaeffer B, Kosanovic M, Lekka ME, Lipps G, Logozzi M, Marcilla A, Sammar M, Llorente A, Nazarenko I, Oliveira C, Pocsfalvi G, Rajendran L, Raposo G, Rohde E, Siljander P, van Niel G, Vasconcelos MH, Yáñez-Mó M, Yliperttula ML, Zarovni N, Zavec AB, Giebel B
Beyond the exome: the role of non-coding somatic mutations in cancer.
Annals of Oncology, February 2016
Piraino SW, Furney SJ.
Obesity Reviews, January 2015
O’Neill S, O’Driscoll L.
Neuromedin U: a multifunctional neuropeptide with pleiotropic roles.
Clinical Chemistry, March 2015
Martinez VG, O’Driscoll L.
Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.
American Journal of Epidemiology, May 2015
Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP.
Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers.
Clinical Chemistry, June 2015
Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM.
Expanding on exosomes and ectosomes in cancer.
New England Journal of Medicine, June 2015
O’Driscoll L.
Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
Advanced Clinical Chemistry, June 2015
Duffy MJ, Walsh S, McDermott EW, Crown J.
IGF-1 Receptor and Adhesion Signaling: An Important Axis in Determining Cancer Cell Phenotype and Therapy Resistance
Frontiers in Endocrinology, July 2015
Cox OT, O’Shea S, Tresse E, Bustamante-Garrido M, Kiran-Deevi R, O’Connor R.
The Role of Exosomes in Breast Cancer.
Clinical Chemistry, December 2015
Lowry MC, Gallagher WM, O’Driscoll L.
PRC2 mediated H3K27 methylations in cellular identity and cancer
Current Opinion Cell Biology, December 2015
Conway E, Healy E, Bracken AP.
Breast Cancer Research, August 2014
Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M.
A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer.
Breast Cancer Research, November 2014
Mulrane L, Gallagher WM, O’Connor DP.
p53 as a target for the treatment of cancer.
Cancer Treatment Reviews, December 2014
Duffy MJ, Synnott NC, McGowan PM, Crown J, O’Connor D, Gallagher WM.
Metabolic syndrome – a closer look at the growing epidemic and its consequences.
Obesity Reviews, January 2015
O’Neill S, O’Driscoll L.
Breast Cancer Research, 2015, October 2013
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O’Connor JP, O’Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.
Breast Cancer Research, July 2017
Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O’Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.
Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer
International Journal of Cancer, June 2017
Martinez VG, Crown J, Porter RK, O’Driscoll L
Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
BMC Medicine, June 2017
Wouters J, Vizoso M, Martinez-Cardus A, Carmona FJ, Govaere O, Laguna T, Joseph J, Dynoodt P, Aura C, Foth M, Cloots R, van den Hurk K, Balint B, Murphy IG, McDermott EW, Sheahan K, Jirström K, Nodin B, Mallya-Udupi G, van den Oord JJ, Gallagher WM, Esteller M
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells
International Journal of Oncology, June 2017
McDermott MSJ, Canonici A, Ivers L, Browne BC, Madden SF, O’Brien NA, Crown J, O’Donovan N.
Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach
Oncotarget, May 2017
Moran B, Das S, Smeets D, Peutman G, Klinger R, Fender B, Connor K, Ebert M, Gaiser T, Prehn JH, Bacon O, Kay E, Hennessy B, Murphy V, Ylstra B, Lambrechts D, Byrne AT, Gallagher WM, O’Connor DP.
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases
JAMA Oncology, May 2017
Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV.
Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib resistant breast cancer models
PLoS One, May 2017
Santra T, Roche S, Conlon N, O’Donovan N, Crown J, O’Connor R, Kolch W
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
Cancer Research. April 2017
Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O’Connor AE, Walsh L, O’Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O’Connor DP, Gallagher WM.
Vitamin D receptor as a target for breast cancer therapy
Endocrine Related Cancer, April 2017
Murray A, Madden SF, Synnott NC, Klinger R, O’Connor D, O’Donovan N, Gallagher W, Crown J, Duffy MJ.
S100β as a serum marker in endocrine resistant breast cancer
BMC Medicine, April 2017
Charmsaz S, Hughes É, Bane FT, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy BT, Dwyer RM, Kerin MJ, Hill AD, Young LS
EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research
Nature Methods, February 2017
Van Deun J, Mestdagh P, Agostinis P, Akay Ö, Anand S, Anckaert J, Martinez ZA, Baetens T, Beghein E, Bertier L, Berx G, Boere J, Boukouris S, Bremer M, Buschmann D, Byrd JB, Casert C, Cheng L, Cmoch A, Daveloose D, De Smedt E, Demirsoy S, Depoorter V, Dhondt B, Driedonks TA, Dudek A, Elsharawy A, Floris I, Foers AD, Gärtner K, Garg AD, Geeurickx E, Gettemans J, Ghazavi F, Giebel B, Kormelink TG, Hancock G, Helsmoortel H, Hill AF, Hyenne V, Kalra H, Kim D, Kowal J, Kraemer S, Leidinger P, Leonelli C, Liang Y, Lippens L, Liu S, Lo Cicero A, Martin S, Mathivanan S, Mathiyalagan P, Matusek T, Milani G, Monguió-Tortajada M, Mus LM, Muth DC, Németh A, Nolte-‘t Hoen EN, O’Driscoll L, Palmulli R, Pfaffl MW, Primdal-Bengtson B, Romano E, Rousseau Q, Sahoo S, Sampaio N, Samuel M, Scicluna B, Soen B, Steels A, Swinnen JV, Takatalo M, Thaminy S, Théry C, Tulkens J, Van Audenhove I, van der Grein S, Van Goethem A, van Herwijnen MJ, Van Niel G, Van Roy N, Van Vliet AR, Vandamme N, Vanhauwaert S, Vergauwen G, Verweij F, Wallaert A, Wauben M, Witwer KW, Zonneveld MI, De Wever O, Vandesompele J
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
British Journal of Cancer, February 2017
Breslin S*, Lowry M*, O’Driscoll L
Identification of coding and non-coding mutational hotspots in cancer genomes
BMC Genomics, January 2017
Piraino SW, Furney SJ
Screening of exosomal microRNAs from colorectal cancer cells
Cancer Biomarkers, January 2017
Cillian Clancy, Sonja Khan, Claire L Glynn, Emma Holian, Peter Dockery, Pierce Lalor, James A.L Brown, Myles R Joyce, Michael J Kerin, Roisin M Dwyer
Patterns of statin initiation and continuation in patients with breast or colorectal cancer, towards end-of-life.
Supportive Care in Cancer, January 2017
Smith A, Murphy L, Bennett K, Barron TI
Science Signalling, November 2016
Halasz M, Kholodenko BN, Kolch W, Santra T
BGRMI: A method for inferring gene regulatory networks from time-course gene expression data and its application in breast cancer research
Scientific Reports, November 2016
Martinez LI, Kolch W, Santra T
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Oncotarget, October 2016
Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ.
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
International Journal of Cancer, September 2016
Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O’Donovan N, O’Connor DP, Gallagher WM, CrownJ, Duffy MJ
De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.
British Journal of Cancer, August 2016
Smith A, Murphy L, Sharp L, O’Connor D, Gallagher WM, Bennett K, Barron TI
AKT1(E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection
BMC Medicine, August 2016
Rudolph M, Anzeneder T, Schulz A, Beckmann G, Byrne AT, Jeffers M, Pena C, Politz O, Köchert K, Vonk R, Reischl J.
A Bayesian algorithm for detecting differentially expressed proteins and its application in breast cancer research
Scientific Reports. July 2016
Santra T, Delatola EI
RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Journal National Cancer Institute, July 2016
Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O’Grady A, Cummins R, Grogan L, Kennedy J, O’Connor D, Young L, Kay EW, O’Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy B
The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance.
Oncotarget, June 2016
Breslin S & O’Driscoll L
Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
Endocrine Related Cancers, April 2016
Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O’Donovan N, Crown J, Duffy MJ.
Lysosome triggered near-infrared fluorescence imaging of cellular trafficking processes in real time.
Nature Communications, March 2016
Grossi M, Morgunova M, Cheung S, Scholz D, Conroy E, Terrile M, Panarella A, Simpson JC, Gallagher WM, O’Shea DF.
AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy irrespective of expression levels and the subcellular localization of Bcl-xL and Bcl-2 in MCF7 cell.
Biochimica et Biophysica Acta (BBA), April 2016
Antonietti P, Gessler F, Düssmann H, Reimertz C, Mittelbronn M, Prehn JH, Kögel D.
Adaptation to AI therapy in breast cancer can induce dynamic alterations in ER activity resulting in estrogen independent metastatic tumours.
Clinical Cancer Research, January 2016
Varešlija D, McBryan J, Fagan A, Redmond AM, Hao Y, Sims AH, Turnbull A, Dixon JM, Ó Gaora P, Hudson L, Purcell S, Hill AD, Young LS.
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
Scientific Reports, January 2016
Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR,Gaber A, O’Hurley G, Lehn S, Muris JJ3, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O’Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R.
Clinical Cancer Research, December, 2015
McBryan J, Fagan A, McCartan D, Bane FT, Varešlija D, Cocchiglia S, Byrne C, Bolger J, McIlroy M, Hudson L, Tibbitts P, O Gaora PO, Hill AD, Young LS.
A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence.
Gene and Development, October 2015
Brien GL, Healy E, Jerman E1, Conway E, Fadda E, O’Donovan D, Krivtsov AV, Rice AM, Kearney CJ, Flaus A, McDade SS, Martin SJ, McLysaght A, O’Connell DJ, Armstrong SA, Bracken AP.
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
Oncotarget, September 2015
O’Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O’Driscoll L.
Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients.
FEBS Journal, July 2015
ALanigan F, Brien GL, Fan Y, Madden SF, Jerman E, Maratha A, Aloraifi F, Hokamp K, Dunne EJ, Lohan AJ, Flanagan L, Garbe JC, Stampfer MR, Fridberg M, Jirstrom K, Quinn CM, Loftus B, Gallagher WM, Geraghty J, Bracken AP.
De-novo post-diagnosis aspirin use and mortality in women with stage I-III breast cancer.
Cancer Epidemiology, Biomarkers and Prevention, June 2015
Barron TI, Murphy LM, Brown C, Bennett K, Visvanathan K, Sharp L.
MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid.
BMC Cancer, May 2015
Khan S, Wall D, Curran C, Newell J, Kerin MJ and Dwyer RM.
Targeting ADAM-17 with an Inhibitory Monoclonal Antibody Has Anti-tumor Effects in Triple-negative Breast Cancer Cells.
British Journal of Cancer, June 2015
Caiazza F, McGowan P, Mullooly M, Murray A, Synnott N, O’Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J, Duffy MJ.
Recent Prediagnostic Aspirin Use, Lymph Node Involvement, and 5-Year Mortality in Women with Stage I-III Breast Cancer: A Nationwide Population-Based Cohort Study.
Cancer Research, August 2014
Barron, T. I., Flahavan, E. M., Sharp, L., Bennett, K., and Visvanathan, K.
Peroxiredoxin-1 protects estrogen receptor alpha from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer
Breast Cancer Research, July 2014
O’Leary, P.C.; Terrile, M., Bajor, M., Gaj, P., Hennessy, B. T., Mills, G. B., Zagozdzon, A., O’Connor, D.P., Brennan, D. J., Connor, K., Li, J.; Gonzalez-Angulo, A. M.; Sun, H. D.; Pu, J. X.; Ponten, F.; Uhlen, M.; Jirstrom, K.; Nowis, D. A.; Crown, J. P.; Zagozdzon, R.; Gallagher, W. M.
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
Neoplasia, July 2014
Rani, S., Corcoran, C., Shiels, L., Germano, S., Breslin, S., Madden, S., McDermott, M. S., Browne, B. C., O’Donovan, N., Crown, J., Gogarty, M.; Byrne, A. T. and O’Driscoll, L.
Link to article
Essential function for PDLIM2 in cell polarization in three-dimensional cultures by feedback regulation of the beta1-integrin-RhoA signaling axis.
Neoplasia, June 2014
Deevi, R. K., Cox, O. T., and O’Connor, R.
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Molecular Cancer, June 2014
McDermott, M. S., Browne, B. C., Conlon, N. T., O’Brien, N. A., Slamon, D. J., Henry, M., Meleady, P., Clynes, M., Dowling, P., Crown, J., and O’Donovan, N
Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis.
Cancer Research, March 2014
Walsh C, Bolger J, Byrne C, Cocchiglia S, Hao Y, Fagan A, Qin Li, Cahalin A, McCartan D, McIlroy M, Ó Gaora P, Xu J, Hill AD, Young LS
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
Molecular Cancer, March 2014
Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, O’Driscoll L
Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.
Oncogene, January 2014
Collins DC, Cocchiglia S, Tibbitts P, Solon G, Bane FT, McBryan J, Treumann A, Eustace A, Hennessy B, Hill AD, Young LS
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis
EMBO Molecular Medicine, December 2013
Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg A, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE
Investigation of molecular alteration of AKT-3 in triple negative breast cancer.
Histopathology, December 2013
O’Hurley G, Daly E, O’Grady A, Cummins R, Quinn C, Flanagan L, Pierce A, Fan Y, Lynn MA, Rafferty M, Fitzgerald D, Pontén F, Duffy MJ, Jirström K, Kay EW, Gallagher WM
Correlating transcriptional networks to breast cancer survival: a large scale coexpression analysis.
Carcinogenesis, October 2013
Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O’Driscoll L, Gallagher WM, Hennessy BT
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Oncotargets, October 2013
Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O’Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O’Donovan N, Crown J, Kong A.